DnB Asset Management
TGTX icon

DnB Asset Management’s TG Therapeutics TGTX Stock Holding History

DnB Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$723K Sell
13,163
-7,652
-37% -$313K ﹤0.01% 688
2026
Q1 		$691K Buy
20,815
+2,970
+17% +$88.5K ﹤0.01% 684
2025
Q4 		$532K Buy
17,845
+3,940
+28% +$129K ﹤0.01% 676
2025
Q3 		$502K Buy
13,905
+3,378
+32% +$111K ﹤0.01% 673
2025
Q2 		$379K Buy
10,527
+3,406
+48% +$127K ﹤0.01% 661
2025
Q1 		$281K Buy
+7,121
New +$240K ﹤0.01% 693

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

DnB Asset Management's TGTX Position: Q2 2026 in Review

DnB Asset Management reduced its TG Therapeutics (TGTX) stake by 37% in Q2 2026, selling an estimated $313K and leaving 13,163 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #688.

DnB Asset Management first reported a position in TGTX in Q1 2025 and has held it in 6 quarters since. 279 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • DnB Asset Management held 13,163 shares of TG Therapeutics worth $723K as of Q2 2026.
  • DnB Asset Management sold 7,652 TG Therapeutics shares in Q2 2026, an estimated $313K.
  • TG Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #688 holding.
  • DnB Asset Management first reported a position in TG Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 279 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.